Spectacle Prescribing in Early Childhood (SPEC)

幼儿期眼镜处方 (SPEC)

• 批准号: 10653907
• 负责人: Erin M Harvey
• 金额: $ 229.26万
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-06-01 至 2025-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10653907
• 关键词: 1 year old; 3 year old; Academy; Address; African American; Age; Age Months; Amblyopia; American; Asian; Astigmatism; Cataract; Child; Childhood; Clinical; Clinical Trials; Consensus; Data; Detection; Development; Device or Instrument Development; Early treatment; Equilibrium; Ethnic Population; Evidence based treatment; Eye; Eye diseases; Eyeglasses; Guidelines; Hispanic; Home; Hyperopia; Infant; Literature; Measures; Medical; Native Americans; Ophthalmology; Outcome; Parents; Performance; Population Study; Protocols documentation; Public Health; Publishing; Recommendation; Refractive Errors; Risk Factors; School-Age Population; Strabismus; Technology; Toddler; Tribes; United States Preventative Services Task Force; Vision; Vision Screening; Visual; Visual Acuity; age group; base; care providers; clinical care; compliance behavior; early childhood; evidence base; evidence based guidelines; experience; improved; instrument; meetings; member; multi-ethnic; pediatrician; prospective; racial population; screening; screening guidelines; wearable device; wearable sensor technology

PROJECT SUMMARY The benefits of early spectacle treatment for moderate refractive error in asymptomatic toddlers are not known. AAPOS spectacle prescribing guidelines for children less than 3 years of age are based on consensus and clinical experience because “there are no scientifically rigorous published data for guidance”. The United States Preventive Services Task Force concluded in 2017 that there is insufficient evidence to assess the balance of benefits of vision screening for children less than 3 years of age because data on the benefits of spectacle correction for refractive error in toddlers are lacking. The SPEC Trial addresses these important gaps in the literature with a focus on assessing the developmental and visual benefits of spectacle treatment for astigmatism in toddlers, and the factors associated with spectacle treatment compliance in this age group. SPEC is a prospective trial to determine if prescribing and providing spectacle correction for astigmatic toddlers (at 12 to < 24 months or 24 to < 36 months of age) meeting current consensus based prescribing guidelines result in better developmental and visual outcome compared to astigmatic children who are prescribed and provided spectacles at age 36 to < 40 months. Developmental outcomes will be measured using the Bayley Scales of Infant and Toddler Development, 3rd Edition. Visual acuity outcome will be measured using the Amblyopia Treatment Study HOTV Protocol. Spectacle treatment compliance will be measured using a wearable sensor attached to the spectacles. The results of the SPEC Trial will have important implications for screening and treatment of young astigmatic children. This study will generate evidence to inform parents, pediatricians, and eye care providers if prescribing spectacles for astigmatic toddlers will have a beneficial effect on their global development, and will allow clinicians to make evidence-based, rather than consensus-based, recommendations regarding treatment of astigmatism in toddlers. The SPEC Trial is also unique in that it includes objective measures of spectacle treatment compliance, and will provide much needed data on factors associated with spectacle treatment compliance in toddlers.

项目摘要 早期眼镜治疗对无症状幼儿中等折射率误差的好处 Aapos眼镜规定了3岁以下儿童的指南 基于共识和临床经验，因为“没有科学严格的 已发布的数据以进行指导”。美国预防服务工作队总结了 2017年，没有足够的证据评估视力筛选的收益平衡 儿童不到3岁，因为有关奇观纠正益处的数据 缺少幼儿中的折射率。规格试验解决了这些重要差距 文学重点是评估奇观的发展和视觉益处 幼儿中散光的治疗以及与眼镜治疗相关的因素 该年龄段的合规性。 规格是一项前瞻性试验，以确定是否处方并提供奇观更正 散光幼儿（12至<24个月或24至<36个月大）会议当前 基于共识的开处方准则会带来更好的发展和视觉结果 与在36至40岁时开处方并提供眼镜的散光儿童相比 月份。发育结果将使用婴儿的贝利量表来衡量 幼儿发展，第三版。视力结果将使用弱视测量 治疗研究HOTV方案。奇观治疗的依从性将使用 可穿戴的传感器连接到眼镜上。 规格试验的结果将对筛查和处理的重要意义 年轻的散光孩子。这项研究将产生证据，以告知父母，儿科医生， 和眼保健提供者，如果开处方散光幼儿的眼镜将有一个有益的 对其全球发展的影响，并将允许临床医生制作基于循证的，而是 而不是基于共识的建议，关于幼儿中散光的建议。 规格试验也是独特的，因为它包括客观的眼镜治疗方法 合规性，并将提供有关与眼镜治疗相关的因素的急需数据 幼儿的合规性。

项目成果

Parent strategies for improving compliance with eyeglass wear in young children.

家长提高幼儿佩戴眼镜依从性的策略。

• DOI: 10.1097/opx.0000000000002123
• 发表时间: 2024
• 期刊: Optometry and vision science : official publication of the American Academy of Optometry
• 作者: Harvey,ErinM;Ramesh,Divya;Marshall,MariaSandra;Martin,JeniferA;McGrath,EileenR;Yescas,Selenne;Miller,JosephM
• 通讯作者: Miller,JosephM

Objective Assessment of Spectacle Wear in Infants and Toddlers Using a Wearable Sensor.

• DOI: 10.1167/tvst.10.9.29
• 发表时间: 2021-08-02
• 期刊: Translational vision science & technology
• 影响因子: 3
• 作者: Miller JM;Dennis LK;Hsu CH;Harvey EM
• 通讯作者: Harvey EM